Iterative Health Expands Team with New Senior Vice President of Technology, Jeremy Freeman, and Vice President of Sales, Scott Lish

Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has expanded its team with two new additions: Jeremy Freeman has joined the company as Senior Vice President of Technology, and Scott Lish has joined as Vice President of Sales.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221027005268/en/

Iterative Health has expanded its team with two new additions: Jeremy Freeman has joined the company as Senior Vice President of Technology, and Scott Lish has joined as Vice President of Sales. (Graphic: Business Wire)

“We’re thrilled to continue expanding our leadership team with the addition of Jeremy and Scott,” said Jonathan Ng, MBBS, founder and CEO of Iterative Health. “Their backgrounds and depth of knowledge will enable us to sustainably scale the team, refine our product, and bring our technology to more patients and physicians. Jeremy and Scott will round out our senior leadership as two distinguished industry veterans who bring over two decades of experience to their respective roles.”

Freeman has a breadth of experience scaling technology teams and will be an essential factor in driving the development of the Iterative Health artificial intelligence (AI) platform. He comes to Iterative Health with insight into consumer products and a deep knowledge of technology and engineering. Prior to joining Iterative Health, Freeman was the SVP of Technology at Thrasio, where he oversaw the software engineering team with a distinct focus on building scalable data platforms and delivering powerful insights with data science. Before Thrasio, he spent seven years at Tripadvisor, where he oversaw consumer-facing engineering on the company’s website and native app, led the development of the subscription-based Tripadvisor Plus platform, and drove multiple efforts to scale engineering teams quickly.

“Every time you have a successful startup, you need to prepare for takeoff,” said Freeman. “Joining Iterative Health at this time has been energizing – the company's computer aided polyp detection device SKOUT™ recently received FDA clearance, and there are exciting advancements underway in their AI-Recruitment platform. I look forward to bringing my experience in product development to the team and catalyzing on this momentum.”

Lish has proven expertise in the gastrointestinal (GI) space, bringing with him twenty years of experience at Boston Scientific. He was most recently the Director of Commercial Contracting and Accounts, where he oversaw commercial product expansion across the Eastern Seaboard. In his new role as VP of Sales, Lish will scale the company’s commercial team, expand the company’s already impressive network of clinical trial sites, and incorporate his nuanced understanding of the healthcare industry.

“Being on the medical device side of gastroenterology for the past twenty years has shown me that there is a tremendous need to utilize technology that will bridge the gaps in GI care,” says Lish. “The need to bring AI to GI is acute, and I am excited to continue to connect this technology to trial sites and patient groups across the country to further efficiency and accuracy in this indication.”

About Iterative Health

Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colonoscopy screenings. We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases.

Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is based in Cambridge, Massachusetts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005268/en/